HC Wainwright Maintains Buy Rating on Enliven Therapeutics, $73 Target
HC Wainwright maintained its Buy rating and $73.00 price target. The target implies 95.6% upside from the Oct. 16 close of $37.32.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.